Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

• Status: Completed
• Trial end date: 2021-05-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cambridge Health Alliance
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• known or suspect COVID-19 disease AND one or more of the following influenza-like symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of breath chest pain

Exclusion Criteria:

• Minors, pregnant women and people unable to provide informed consent are excluded from this study